2022
An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study
Geisen C, Kjaer M, Fleck E, Skogen B, Armstrong R, Behrens F, Bhagwagar Z, Braeuninger S, Mortberg A, Olsen K, Gastón Schäfer S, Walter C, Seifried E, Wikman A, Kjeldsen-Kragh J, Koehm M. An HPA-1a–positive platelet–depleting agent for prevention of fetal and neonatal alloimmune thrombocytopenia: a randomized, single-blind, placebo–controlled, single-center, phase 1/2 proof-of-concept study. Journal Of Thrombosis And Haemostasis 2022, 21: 838-849. PMID: 36696185, DOI: 10.1016/j.jtha.2022.11.041.Peer-Reviewed Original ResearchConceptsFetal/Neonatal Alloimmune ThrombocytopeniaNeonatal alloimmune thrombocytopeniaHPA-1aAlloimmune thrombocytopeniaHuman platelet antigen 1aTreatment-emergent adverse eventsPlacebo 1 hourHPA-1a antibodiesFNAIT casesHyperimmune IgGPrimary endpointAdverse eventsFetus/Healthy menSingle doseAntigen 1aHLA-A2Concept studyCohort 1PlaceboFlow cytometryThrombocytopeniaPlateletsAdministrationWeeks
2005
Lamotrigine in the treatment of bipolar disorder
Bhagwagar Z, Goodwin G. Lamotrigine in the treatment of bipolar disorder. Expert Opinion On Pharmacotherapy 2005, 6: 1401-1408. PMID: 16013989, DOI: 10.1517/14656566.6.8.1401.Peer-Reviewed Original ResearchConceptsBipolar disorderIncidence of rashCommon side effectsLong-term treatmentTreatment of epilepsyCareful prescribingPivotal trialsNovel anticonvulsant agentGlutamatergic functionMood disordersSide effectsPsychiatric conditionsAnticonvulsant agentsMode of actionIon channel conductanceDisordersLamotrigineLong-term basisTreatmentEfficacyPlaceboRashPrescribingHeadachePatients